25 XP   0   0   10

Alnylam Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Alnylam together

PenkeI guess you are interested in Alnylam Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Alnylam Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Alnylam Pharmaceuticals Inc

I send you an email if I find something interesting about Alnylam Pharmaceuticals Inc.

Quick analysis of Alnylam (30 sec.)










What can you expect buying and holding a share of Alnylam? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-1.75
Expected worth in 1 year
$-2.25
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$-0.50
Return On Investment
-0.3%

For what price can you sell your share?

Current Price per Share
$154.39
Expected price per share
$122.57 - $199.38
How sure are you?
50%

1. Valuation of Alnylam (5 min.)




Live pricePrice per Share (EOD)

$154.39

Intrinsic Value Per Share

$-28.38 - $14.75

Total Value Per Share

$-30.13 - $13.00

2. Growth of Alnylam (5 min.)




Is Alnylam growing?

Current yearPrevious yearGrowGrow %
How rich?-$220.6m$87.8m-$351.3m-133.3%

How much money is Alnylam making?

Current yearPrevious yearGrowGrow %
Making money-$110m-$282.7m$172.7m156.9%
Net Profit Margin-38.2%-112.9%--

How much money comes from the company's main activities?

3. Financial Health of Alnylam (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#1022 / 1031

Most Revenue
#33 / 1031

Most Profit
#996 / 1031

Most Efficient
#543 / 1031

What can you expect buying and holding a share of Alnylam? (5 min.)

Welcome investor! Alnylam's management wants to use your money to grow the business. In return you get a share of Alnylam.

What can you expect buying and holding a share of Alnylam?

First you should know what it really means to hold a share of Alnylam. And how you can make/lose money.

Speculation

The Price per Share of Alnylam is $154.39. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alnylam.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alnylam, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.75. Based on the TTM, the Book Value Change Per Share is $-0.12 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.48 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alnylam.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.09-0.7%-0.89-0.6%-2.25-1.5%-1.66-1.1%-1.29-0.8%
Usd Book Value Change Per Share-0.49-0.3%-0.12-0.1%-1.48-1.0%-0.60-0.4%-0.10-0.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.49-0.3%-0.12-0.1%-1.48-1.0%-0.60-0.4%-0.10-0.1%
Usd Price Per Share191.41-189.69-186.74-153.45-118.76-
Price to Earnings Ratio-43.71--15.56--22.38--19.17--26.26-
Price-to-Total Gains Ratio-391.44--178.08--156.36--111.22--131.98-
Price to Book Ratio-109.26--101.36--101.57--30.79--11.03-
Price-to-Total Gains Ratio-391.44--178.08--156.36--111.22--131.98-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share154.39
Number of shares6
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.12-0.60
Usd Total Gains Per Share-0.12-0.60
Gains per Quarter (6 shares)-0.74-3.63
Gains per Year (6 shares)-2.97-14.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-3-130-15-25
20-6-160-29-40
30-9-190-44-55
40-12-220-58-70
50-15-250-73-85
60-18-280-87-100
70-21-310-102-115
80-24-340-116-130
90-27-370-131-145
100-30-400-145-160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%1.039.00.02.5%2.079.00.02.5%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%4.016.00.020.0%9.031.00.022.5%20.061.00.024.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.081.00.0%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%4.016.00.020.0%9.031.00.022.5%20.061.00.024.7%

Fundamentals of Alnylam

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-03-20 09:24:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Alnylam Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Alnylam earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Alnylam to the Biotechnology industry mean.
  • A Net Profit Margin of -31.4% means that $-0.31 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is -31.4%. The company is making a huge loss. -2
  • The TTM is -38.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-31.4%TTM-38.2%+6.8%
TTM-38.2%YOY-112.9%+74.7%
TTM-38.2%5Y-171.9%+133.7%
5Y-171.9%10Y-784.6%+612.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-31.4%-171.8%+140.4%
TTM-38.2%-205.8%+167.6%
YOY-112.9%-262.1%+149.2%
5Y-171.9%-455.6%+283.7%
10Y-784.6%-589.0%-195.6%
1.1.2. Return on Assets

Shows how efficient Alnylam is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Alnylam to the Biotechnology industry mean.
  • -3.6% Return on Assets means that Alnylam generated $-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is -3.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.6%TTM-3.2%-0.4%
TTM-3.2%YOY-8.2%+4.9%
TTM-3.2%5Y-6.8%+3.5%
5Y-6.8%10Y-7.5%+0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.6%-12.5%+8.9%
TTM-3.2%-12.2%+9.0%
YOY-8.2%-11.2%+3.0%
5Y-6.8%-13.4%+6.6%
10Y-7.5%-14.7%+7.2%
1.1.3. Return on Equity

Shows how efficient Alnylam is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Alnylam to the Biotechnology industry mean.
  • 0.0% Return on Equity means Alnylam generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-54.4%+54.4%
TTM-5Y-23.0%+23.0%
5Y-23.0%10Y-16.3%-6.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.8%+15.8%
TTM--15.7%+15.7%
YOY-54.4%-13.9%-40.5%
5Y-23.0%-18.3%-4.7%
10Y-16.3%-19.2%+2.9%

1.2. Operating Efficiency of Alnylam Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Alnylam is operating .

  • Measures how much profit Alnylam makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Alnylam to the Biotechnology industry mean.
  • An Operating Margin of -26.5% means the company generated $-0.26  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is -26.5%. The company is operating very inefficient. -2
  • The TTM is -32.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-26.5%TTM-32.2%+5.7%
TTM-32.2%YOY-77.0%+44.8%
TTM-32.2%5Y-168.6%+136.4%
5Y-168.6%10Y-690.9%+522.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-26.5%-299.1%+272.6%
TTM-32.2%-210.1%+177.9%
YOY-77.0%-279.7%+202.7%
5Y-168.6%-459.9%+291.3%
10Y-690.9%-596.9%-94.0%
1.2.2. Operating Ratio

Measures how efficient Alnylam is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.26 means that the operating costs are $1.26 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is 1.265. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.292. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.265TTM1.292-0.028
TTM1.292YOY1.770-0.477
TTM1.2925Y2.644-1.352
5Y2.64410Y12.042-9.398
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2652.861-1.596
TTM1.2923.193-1.901
YOY1.7703.615-1.845
5Y2.6445.560-2.916
10Y12.0427.396+4.646

1.3. Liquidity of Alnylam Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Alnylam is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.08 means the company has $3.08 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is 3.082. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.320. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.082TTM3.320-0.238
TTM3.320YOY3.755-0.435
TTM3.3205Y4.003-0.684
5Y4.00310Y7.068-3.064
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0823.986-0.904
TTM3.3204.440-1.120
YOY3.7555.552-1.797
5Y4.0036.158-2.155
10Y7.0686.492+0.576
1.3.2. Quick Ratio

Measures if Alnylam is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Alnylam to the Biotechnology industry mean.
  • A Quick Ratio of 4.54 means the company can pay off $4.54 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is 4.540. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.780. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.540TTM4.780-0.240
TTM4.780YOY5.533-0.753
TTM4.7805Y5.754-0.975
5Y5.75410Y10.471-4.716
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5403.638+0.902
TTM4.7804.168+0.612
YOY5.5335.515+0.018
5Y5.7546.012-0.258
10Y10.4716.209+4.262

1.4. Solvency of Alnylam Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Alnylam assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Alnylam to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.06 means that Alnylam assets are financed with 105.8% credit (debt) and the remaining percentage (100% - 105.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is 1.058. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.074. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.058TTM1.074-0.017
TTM1.074YOY0.974+0.101
TTM1.0745Y0.748+0.326
5Y0.74810Y0.445+0.303
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0580.335+0.723
TTM1.0740.330+0.744
YOY0.9740.267+0.707
5Y0.7480.367+0.381
10Y0.4450.378+0.067
1.4.2. Debt to Equity Ratio

Measures if Alnylam is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Alnylam to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY6.369-6.369
TTM-5Y2.408-2.408
5Y2.40810Y1.290+1.118
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.376-0.376
TTM-0.398-0.398
YOY6.3690.334+6.035
5Y2.4080.429+1.979
10Y1.2900.476+0.814

2. Market Valuation of Alnylam Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Alnylam generates.

  • Above 15 is considered overpriced but always compare Alnylam to the Biotechnology industry mean.
  • A PE ratio of -43.71 means the investor is paying $-43.71 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alnylam Pharmaceuticals Inc:

  • The EOD is -35.259. Based on the earnings, the company is expensive. -2
  • The MRQ is -43.714. Based on the earnings, the company is expensive. -2
  • The TTM is -15.563. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-35.259MRQ-43.714+8.455
MRQ-43.714TTM-15.563-28.151
TTM-15.563YOY-22.384+6.821
TTM-15.5635Y-19.173+3.610
5Y-19.17310Y-26.256+7.083
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-35.259-2.643-32.616
MRQ-43.714-2.418-41.296
TTM-15.563-2.742-12.821
YOY-22.384-4.123-18.261
5Y-19.173-6.257-12.916
10Y-26.256-6.478-19.778
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alnylam Pharmaceuticals Inc:

  • The EOD is -107.778. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -133.621. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -57.861. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-107.778MRQ-133.621+25.843
MRQ-133.621TTM-57.861-75.759
TTM-57.861YOY-39.199-18.663
TTM-57.8615Y-32.721-25.140
5Y-32.72110Y-35.027+2.306
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-107.778-3.244-104.534
MRQ-133.621-2.939-130.682
TTM-57.861-3.478-54.383
YOY-39.199-5.592-33.607
5Y-32.721-8.473-24.248
10Y-35.027-8.881-26.146
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Alnylam is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -109.26 means the investor is paying $-109.26 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alnylam Pharmaceuticals Inc:

  • The EOD is -88.127. Based on the equity, the company is expensive. -2
  • The MRQ is -109.259. Based on the equity, the company is expensive. -2
  • The TTM is -101.357. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-88.127MRQ-109.259+21.131
MRQ-109.259TTM-101.357-7.902
TTM-101.357YOY-101.567+0.210
TTM-101.3575Y-30.791-70.565
5Y-30.79110Y-11.027-19.765
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-88.1272.124-90.251
MRQ-109.2592.041-111.300
TTM-101.3572.118-103.475
YOY-101.5672.915-104.482
5Y-30.7913.682-34.473
10Y-11.0274.114-15.141
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Alnylam Pharmaceuticals Inc.

3.1. Institutions holding Alnylam Pharmaceuticals Inc

Institutions are holding 95.239% of the shares of Alnylam Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Capital World Investors12.84250.550616174563-354745-2.1462
2023-12-31Vanguard Group Inc9.48340.0499119438952870642.4626
2023-12-31FMR Inc8.18790.151610312356-969050-8.5898
2023-12-31BlackRock Inc6.76570.041685211151281111.5264
2023-12-31Wellington Management Company LLP5.7280.2575721419878238412.1643
2023-12-31Baillie Gifford & Co Limited.5.53181.05686967097-1196042-14.6517
2023-12-31Dodge & Cox2.91740.44643674310-72845-1.944
2023-12-31Capital Research & Mgmt Co - Division 32.84780.1539358665748881415.7792
2023-12-31T. Rowe Price Associates, Inc.2.76620.08963483969-441035-11.2365
2023-12-31T. Rowe Price Investment Management,Inc.2.72030.42643426063272040.8004
2023-12-31State Street Corporation2.47610.02931185522190397.5543
2023-12-31JPMorgan Chase & Co2.39480.05553016141-70705-2.2905
2023-12-31Capital Research Global Investors2.32650.13829300791462365.253
2023-12-31NORGES BANK1.61960.068220397981026952101.3927
2023-12-31Geode Capital Management, LLC1.52980.03851926736872314.7421
2023-12-31RTW INVESTMENTS, LLC1.30264.90511640559-42803-2.5427
2023-12-31venBio Select Advisor LLC0.88222.937611111111000009.8901
2023-12-31Legal & General Group PLC0.73920.045793093913626817.1477
2023-12-31Pictet Asset Manangement SA0.70310.1878855859483011.9923
2023-12-31Bellevue Group AG0.70292.5921885318-9027-1.0093
Total 74.467814.22193789041+367881+0.4%

3.2. Funds holding Alnylam Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Capital Group Growth Fnd of Amer Comp6.44880.624381220131885912.3772
2023-12-31American Funds Growth Fund of Amer A6.44880.624381220131885912.3772
2023-12-31Vanguard Health Care Inv4.38672.2784552490356498511.391
2024-02-29Vanguard Total Stock Mkt Idx Inv3.13770.03853951754-9362-0.2363
2023-12-31VA CollegeAmerica Amcap 529A2.6490.7948333632333888311.3057
2023-12-31Capital Group AMCAP Composite2.6490.7948333632333888311.3057
2023-12-31Capital Group New Perspective Comp2.6350.50143318681-168251-4.8252
2023-12-31American Funds New Perspective A2.6350.50143318681-168251-4.8252
2024-02-29Vanguard Mid Cap Index Institutional2.12410.25242675266-7444-0.2775
2023-12-31American Funds Fundamental Invs A2.08520.4022626264575442.2402
2023-12-31Capital Group Fundamental Invtrs Comp2.08520.4022626264575442.2402
2023-12-31Dodge & Cox Stock I1.8630.44492346400-50800-2.1191
2023-12-31Capital Group Growth Composite1.68451.0333212150800
2023-12-31American Funds IS® Growth 11.68451.0333212150800
2024-01-31Fidelity Growth Compy Commingled Pl O1.51340.45951906033-50226-2.5675
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.4740.2749185639425180.1358
2023-12-31T. Rowe Price US Mid-Cap Growth Equity1.32661.05271670800-3900-0.2329
2023-12-31T. Rowe Price Mid-Cap Growth1.32661.0561670800-3900-0.2329
2023-12-31American Funds New Economy A1.16160.9106146293000
2023-12-31Capital Group New Economy Comp1.16160.9106146293000
Total 50.480314.390163577788+1275405+2.0%

3.3. Insider Transactions

Insiders are holding 0.396% of the shares of Alnylam Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-27Michael W BonneySELL30000195
2023-08-07Pushkal GargSELL4166183.89
2023-08-04Jeffrey V PoultonSELL3460185.85
2023-08-04Pushkal GargSELL3461185.85
2023-08-04Yvonne GreenstreetSELL4057185.85
2023-04-27Akshay VaishnawSELL2392194.59
2023-04-27Jeffrey V PoultonSELL977194.59
2023-04-27Pushkal GargSELL1839194.59
2023-04-27Tolga TangulerSELL1476194.59
2023-04-27Yvonne GreenstreetSELL7615194.59
2023-04-06Indrani Lall FranchiniSELL3500210

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Alnylam Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.489-0.124-75%-1.482+203%-0.604+24%-0.097-80%
Book Value Per Share---1.752-2.078+19%0.697-351%5.462-132%7.572-123%
Current Ratio--3.0823.320-7%3.755-18%4.003-23%7.068-56%
Debt To Asset Ratio--1.0581.074-2%0.974+9%0.748+41%0.445+138%
Debt To Equity Ratio----0%6.369-100%2.408-100%1.290-100%
Dividend Per Share----0%-0%-0%-0%
Eps---1.095-0.886-19%-2.245+105%-1.657+51%-1.288+18%
Free Cash Flow Per Share---0.3580.055-747%-1.217+240%-0.956+167%-0.860+140%
Free Cash Flow To Equity Per Share---0.0470.394-112%-0.372+698%0.498-109%0.407-111%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--14.750--------
Intrinsic Value_10Y_min---28.381--------
Intrinsic Value_1Y_max---2.732--------
Intrinsic Value_1Y_min---3.368--------
Intrinsic Value_3Y_max---5.000--------
Intrinsic Value_3Y_min---9.727--------
Intrinsic Value_5Y_max---3.400--------
Intrinsic Value_5Y_min---15.604--------
Market Cap19444802940.000-24%24107323860.00024129698130.0000%23518841175.000+3%19373836140.000+24%14980585882.500+61%
Net Profit Margin---0.314-0.382+22%-1.129+260%-1.719+448%-7.846+2402%
Operating Margin---0.265-0.322+22%-0.770+191%-1.686+537%-6.909+2510%
Operating Ratio--1.2651.292-2%1.770-29%2.644-52%12.042-89%
Pb Ratio-88.127+19%-109.259-101.357-7%-101.567-7%-30.791-72%-11.027-90%
Pe Ratio-35.259+19%-43.714-15.563-64%-22.384-49%-19.173-56%-26.256-40%
Price Per Share154.390-24%191.410189.693+1%186.738+3%153.448+25%118.755+61%
Price To Free Cash Flow Ratio-107.778+19%-133.621-57.861-57%-39.199-71%-32.721-76%-35.027-74%
Price To Total Gains Ratio-315.733+19%-391.440-178.078-55%-156.356-60%-111.221-72%-131.978-66%
Quick Ratio--4.5404.780-5%5.533-18%5.754-21%10.471-57%
Return On Assets---0.036-0.032-10%-0.082+127%-0.068+88%-0.075+107%
Return On Equity----0%-0.5440%-0.2300%-0.1630%
Total Gains Per Share---0.489-0.124-75%-1.482+203%-0.604+24%-0.097-80%
Usd Book Value---220644000.000-263470250.000+19%87836250.000-351%687589850.000-132%953469050.000-123%
Usd Book Value Change Per Share---0.489-0.124-75%-1.482+203%-0.604+24%-0.097-80%
Usd Book Value Per Share---1.752-2.078+19%0.697-351%5.462-132%7.572-123%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.095-0.886-19%-2.245+105%-1.657+51%-1.288+18%
Usd Free Cash Flow---45104000.00010486250.000-530%-153333250.000+240%-119667900.000+165%-107970150.000+139%
Usd Free Cash Flow Per Share---0.3580.055-747%-1.217+240%-0.956+167%-0.860+140%
Usd Free Cash Flow To Equity Per Share---0.0470.394-112%-0.372+698%0.498-109%0.407-111%
Usd Market Cap19444802940.000-24%24107323860.00024129698130.0000%23518841175.000+3%19373836140.000+24%14980585882.500+61%
Usd Price Per Share154.390-24%191.410189.693+1%186.738+3%153.448+25%118.755+61%
Usd Profit---137870000.000-110060500.000-20%-282789000.000+105%-208430950.000+51%-162039150.000+18%
Usd Revenue--439718000.000457073000.000-4%259354500.000+70%221130000.000+99%118155925.000+272%
Usd Total Gains Per Share---0.489-0.124-75%-1.482+203%-0.604+24%-0.097-80%
 EOD+2 -6MRQTTM+11 -20YOY+24 -85Y+22 -1010Y+18 -14

4.2. Fundamental Score

Let's check the fundamental score of Alnylam Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-35.259
Price to Book Ratio (EOD)Between0-1-88.127
Net Profit Margin (MRQ)Greater than0-0.314
Operating Margin (MRQ)Greater than0-0.265
Quick Ratio (MRQ)Greater than14.540
Current Ratio (MRQ)Greater than13.082
Debt to Asset Ratio (MRQ)Less than11.058
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.036
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Alnylam Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.162
Ma 20Greater thanMa 50149.493
Ma 50Greater thanMa 100161.829
Ma 100Greater thanMa 200169.685
OpenGreater thanClose152.830
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets3,829,880
Total Liabilities4,050,524
Total Stockholder Equity-220,644
 As reported
Total Liabilities 4,050,524
Total Stockholder Equity+ -220,644
Total Assets = 3,829,880

Assets

Total Assets3,829,880
Total Current Assets2,982,697
Long-term Assets847,183
Total Current Assets
Cash And Cash Equivalents 812,688
Short-term Investments 1,626,694
Net Receivables 327,787
Inventory 89,146
Other Current Assets 126,382
Total Current Assets  (as reported)2,982,697
Total Current Assets  (calculated)2,982,697
+/-0
Long-term Assets
Property Plant Equipment 725,789
Long-term Assets Other 69,807
Long-term Assets  (as reported)847,183
Long-term Assets  (calculated)795,596
+/- 51,587

Liabilities & Shareholders' Equity

Total Current Liabilities967,786
Long-term Liabilities3,082,738
Total Stockholder Equity-220,644
Total Current Liabilities
Short-term Debt 96,501
Accounts payable 55,519
Other Current Liabilities 713,013
Total Current Liabilities  (as reported)967,786
Total Current Liabilities  (calculated)865,033
+/- 102,753
Long-term Liabilities
Long term Debt 1,020,776
Capital Lease Obligations 284,611
Long-term Liabilities Other 1,630,686
Long-term Liabilities  (as reported)3,082,738
Long-term Liabilities  (calculated)2,936,073
+/- 146,665
Total Stockholder Equity
Common Stock1,259
Retained Earnings -7,009,591
Accumulated Other Comprehensive Income -23,375
Other Stockholders Equity 6,811,063
Total Stockholder Equity (as reported)-220,644
Total Stockholder Equity (calculated)-220,644
+/-0
Other
Capital Stock1,259
Cash and Short Term Investments 2,439,382
Common Stock Shares Outstanding 125,613
Current Deferred Revenue102,753
Liabilities and Stockholders Equity 3,829,880
Net Debt 1,869,938
Net Invested Capital 800,132
Net Working Capital 2,014,911
Property Plant and Equipment Gross 948,865
Short Long Term Debt Total 2,682,626



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-31
> Total Assets 
16,111
0
0
0
35,183
39,339
68,473
62,545
66,107
59,067
50,862
43,248
98,348
153,687
147,114
144,527
240,006
227,340
219,658
505,091
493,791
486,256
580,046
580,181
554,676
554,529
518,653
495,668
481,385
463,406
440,180
412,606
393,265
369,052
340,828
310,223
281,917
340,295
318,477
322,352
287,520
471,578
462,558
447,503
420,530
1,080,297
1,032,659
986,357
1,079,595
1,628,790
1,530,771
1,436,144
1,386,510
1,316,949
1,382,162
1,312,910
1,262,810
1,133,926
1,434,283
1,358,281
1,994,730
1,923,139
1,789,389
1,675,654
1,574,802
2,013,999
2,716,411
2,541,622
2,395,134
2,279,624
3,374,367
3,307,283
3,407,061
3,255,269
3,509,429
3,472,313
3,643,304
3,433,545
3,330,417
3,535,255
3,546,359
3,391,940
3,402,396
3,839,073
3,829,880
3,829,8803,839,0733,402,3963,391,9403,546,3593,535,2553,330,4173,433,5453,643,3043,472,3133,509,4293,255,2693,407,0613,307,2833,374,3672,279,6242,395,1342,541,6222,716,4112,013,9991,574,8021,675,6541,789,3891,923,1391,994,7301,358,2811,434,2831,133,9261,262,8101,312,9101,382,1621,316,9491,386,5101,436,1441,530,7711,628,7901,079,595986,3571,032,6591,080,297420,530447,503462,558471,578287,520322,352318,477340,295281,917310,223340,828369,052393,265412,606440,180463,406481,385495,668518,653554,529554,676580,181580,046486,256493,791505,091219,658227,340240,006144,527147,114153,68798,34843,24850,86259,06766,10762,54568,47339,33935,18300016,111
   > Total Current Assets 
0
0
0
0
24,189
22,586
50,511
47,198
48,181
41,442
33,840
26,697
82,414
137,120
129,057
126,827
222,784
209,916
201,958
477,632
463,559
455,475
550,631
451,779
442,249
419,339
278,422
228,165
293,534
273,309
409,297
244,623
254,139
348,917
322,414
293,175
152,028
208,539
304,083
303,415
228,973
404,929
214,359
199,164
358,630
1,009,088
966,256
926,265
1,026,188
1,573,957
1,485,948
1,041,793
1,358,698
1,246,201
888,068
747,564
989,241
597,188
960,709
993,368
1,782,830
1,691,160
1,502,559
1,342,120
1,209,319
1,401,050
2,073,460
1,897,265
1,733,933
1,584,773
2,160,446
2,054,702
2,159,822
1,970,083
2,725,163
2,675,362
2,868,780
2,589,677
2,471,638
2,690,847
2,692,247
2,541,018
2,524,047
2,985,452
2,982,697
2,982,6972,985,4522,524,0472,541,0182,692,2472,690,8472,471,6382,589,6772,868,7802,675,3622,725,1631,970,0832,159,8222,054,7022,160,4461,584,7731,733,9331,897,2652,073,4601,401,0501,209,3191,342,1201,502,5591,691,1601,782,830993,368960,709597,188989,241747,564888,0681,246,2011,358,6981,041,7931,485,9481,573,9571,026,188926,265966,2561,009,088358,630199,164214,359404,929228,973303,415304,083208,539152,028293,175322,414348,917254,139244,623409,297273,309293,534228,165278,422419,339442,249451,779550,631455,475463,559477,632201,958209,916222,784126,827129,057137,12082,41426,69733,84041,44248,18147,19850,51122,58624,1890000
       Cash And Cash Equivalents 
15,477
0
0
0
23,193
21,612
31,891
14,544
20,272
12,215
9,165
7,178
15,757
56,804
35,645
35,516
127,955
66,662
84,464
200,547
105,157
196,281
247,536
196,737
191,792
227,268
147,870
98,087
137,468
114,947
66,182
46,881
74,599
90,590
67,110
74,336
70,228
61,739
48,274
75,838
51,405
97,804
24,975
11,840
53,169
350,589
80,727
82,721
881,929
1,450,754
1,396,800
149,218
1,280,951
231,278
271,076
168,481
193,617
171,079
408,671
202,045
645,361
396,149
361,457
316,608
420,146
724,959
1,136,289
923,304
547,178
467,779
580,829
496,704
496,580
379,543
745,767
1,093,991
819,975
534,081
575,558
1,073,228
866,394
672,245
657,800
1,033,024
812,688
812,6881,033,024657,800672,245866,3941,073,228575,558534,081819,9751,093,991745,767379,543496,580496,704580,829467,779547,178923,3041,136,289724,959420,146316,608361,457396,149645,361202,045408,671171,079193,617168,481271,076231,2781,280,951149,2181,396,8001,450,754881,92982,72180,727350,58953,16911,84024,97597,80451,40575,83848,27461,73970,22874,33667,11090,59074,59946,88166,182114,947137,46898,087147,870227,268191,792196,737247,536196,281105,157200,54784,46466,662127,95535,51635,64556,80415,7577,1789,16512,21520,27214,54431,89121,61223,19300015,477
       Short-term Investments 
19
0
0
0
373
0
14,207
30,393
25,774
26,075
22,477
17,631
64,245
75,471
87,622
84,758
89,305
137,804
110,304
267,831
350,445
247,592
290,787
223,379
238,596
180,786
119,368
119,883
143,934
146,811
193,012
184,486
158,532
154,050
150,839
98,685
76,174
137,356
180,750
152,498
71,407
138,207
184,719
181,939
192,701
314,901
574,035
549,213
94,583
99,890
64,628
866,992
51,419
782,356
585,326
544,655
433,182
388,525
514,600
746,249
1,045,257
1,171,715
1,086,209
920,226
664,009
519,578
790,542
797,754
988,984
874,424
1,344,735
1,337,172
1,377,815
1,329,994
1,154,315
1,233,874
1,615,589
1,705,482
1,535,055
1,192,101
1,326,012
1,398,430
1,399,707
1,373,254
1,626,694
1,626,6941,373,2541,399,7071,398,4301,326,0121,192,1011,535,0551,705,4821,615,5891,233,8741,154,3151,329,9941,377,8151,337,1721,344,735874,424988,984797,754790,542519,578664,009920,2261,086,2091,171,7151,045,257746,249514,600388,525433,182544,655585,326782,35651,419866,99264,62899,89094,583549,213574,035314,901192,701181,939184,719138,20771,407152,498180,750137,35676,17498,685150,839154,050158,532184,486193,012146,811143,934119,883119,368180,786238,596223,379290,787247,592350,445267,831110,304137,80489,30584,75887,62275,47164,24517,63122,47726,07525,77430,39314,207037300019
       Net Receivables 
0
0
0
0
0
0
3,000
916
1,169
2,164
960
587
755
3,116
3,591
4,847
3,829
4,393
5,615
5,129
5,031
9,680
5,126
24,140
4,188
5,831
5,857
5,022
6,044
4,505
6,358
4,881
14,119
1,150
1,308
2,027
1,468
2,192
4,385
1,918
104
558
460
609
4,248
164
89
384
39,937
10,107
9,403
8,130
8,298
8,814
9,514
15,146
23,334
19,457
15,405
14,644
34,002
50,768
2,961
3,362
18,760
33,801
30,739
48,109
43,011
75,572
69,115
79,118
102,413
110,626
646,587
141,064
198,571
156,533
142,271
184,513
237,963
219,434
220,635
325,445
327,787
327,787325,445220,635219,434237,963184,513142,271156,533198,571141,064646,587110,626102,41379,11869,11575,57243,01148,10930,73933,80118,7603,3622,96150,76834,00214,64415,40519,45723,33415,1469,5148,8148,2988,1309,40310,10739,937384891644,2486094605581041,9184,3852,1921,4682,0271,3081,15014,1194,8816,3584,5056,0445,0225,8575,8314,18824,1405,1269,6805,0315,1295,6154,3933,8294,8473,5913,1167555879602,1641,1699163,000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-253,173
0
0
-239,721
-212,872
-168,112
0
0
-222,091
-222,657
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,081
24,068
32,001
40,587
54,562
56,348
68,300
77,418
66,942
92,302
73,940
84,358
97,899
122,701
78,516
88,976
115,489
128,962
131,879
100,453
95,771
89,146
89,14695,771100,453131,879128,962115,48988,97678,516122,70197,89984,35873,94092,30266,94277,41868,30056,34854,56240,58732,00124,06811,08100000000000000000000000-222,657-222,09100-168,112-212,872-239,72100-253,173000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
10,994
16,753
17,962
15,347
17,926
17,625
17,022
16,551
15,934
16,567
18,057
17,700
17,222
17,424
17,700
27,459
30,232
30,781
29,415
128,402
112,427
135,190
240,231
267,503
187,851
190,097
30,883
167,983
139,126
20,135
18,414
17,048
129,889
131,756
14,394
18,937
58,547
66,649
248,199
248,339
61,900
71,209
66,403
60,092
53,407
54,833
44,823
394,351
27,812
70,748
494,094
565,346
273,569
536,738
473,574
364,913
211,900
231,979
286,830
333,534
365,483
612,949
642,951
644,357
661,201
694,851
1,213,921
1,252,581
1,247,239
1,285,186
784,266
796,951
774,524
843,868
858,779
844,408
854,112
850,922
878,349
853,621
847,183
847,183853,621878,349850,922854,112844,408858,779843,868774,524796,951784,2661,285,1861,247,2391,252,5811,213,921694,851661,201644,357642,951612,949365,483333,534286,830231,979211,900364,913473,574536,738273,569565,346494,09470,74827,812394,35144,82354,83353,40760,09266,40371,20961,900248,339248,19966,64958,54718,93714,394131,756129,88917,04818,41420,135139,126167,98330,883190,097187,851267,503240,231135,190112,427128,40229,41530,78130,23227,45917,70017,42417,22217,70018,05716,56715,93416,55117,02217,62517,92615,34717,96216,75310,9940000
       Property Plant Equipment 
526
0
0
0
4,756
8,961
11,436
8,969
11,694
11,540
11,084
10,760
10,580
11,359
13,044
12,856
12,173
12,527
12,965
10,434
13,810
15,875
18,853
19,577
19,194
19,321
18,483
18,152
18,324
18,304
18,554
18,399
18,289
17,021
16,252
15,309
14,643
13,703
14,206
18,792
19,799
18,983
18,045
16,974
16,448
15,731
16,953
18,806
21,740
21,166
25,169
26,316
27,812
36,814
55,394
74,219
114,572
129,962
147,533
161,899
181,900
201,979
227,839
272,652
320,658
568,124
598,126
619,900
646,376
651,094
668,800
689,924
706,514
701,785
708,789
720,794
733,633
733,158
732,122
733,623
738,630
738,081
736,275
729,076
725,789
725,789729,076736,275738,081738,630733,623732,122733,158733,633720,794708,789701,785706,514689,924668,800651,094646,376619,900598,126568,124320,658272,652227,839201,979181,900161,899147,533129,962114,57274,21955,39436,81427,81226,31625,16921,16621,74018,80616,95315,73116,44816,97418,04518,98319,79918,79214,20613,70314,64315,30916,25217,02118,28918,39918,55418,30418,32418,15218,48319,32119,19419,57718,85315,87513,81010,43412,96512,52712,17312,85613,04411,35910,58010,76011,08411,54011,6948,96911,4368,9614,756000526
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
138,907
140,523
120,389
100,917
99,881
114,639
114,971
117,822
63,741
67,482
142,164
212,484
230,154
231,365
150,054
390,503
350,585
324,534
279,821
483,771
456,798
358,629
251,839
228,590
287,229
339,566
324,799
255,305
174,570
51,543
13,919
648
0
0
0
44,825
44,825
14,825
14,825
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000014,82514,82544,82544,82500064813,91951,543174,570255,305324,799339,566287,229228,590251,839358,629456,798483,771279,821324,534350,585390,503150,054231,365230,154212,484142,16467,48263,741117,822114,971114,63999,881100,917120,389140,523138,907000000000000000000000000000000
       Intangible Assets 
0
0
0
0
3,878
3,760
3,642
3,523
3,405
3,287
3,168
3,050
2,491
2,387
2,284
2,180
1,933
1,835
1,737
1,610
968
925
882
838
795
751
708
665
622
578
535
491
448
405
361
318
275
231
188
145
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000001451882312753183614054484915355786226657087517958388829259681,6101,7371,8351,9332,1802,2842,3872,4913,0503,1683,2873,4053,5233,6423,7603,8780000
       Long-term Assets Other 
0
0
0
0
2,360
4,032
2,884
2,855
2,827
2,798
2,770
2,741
2,863
2,821
2,729
2,664
3,116
3,062
2,998
15,415
15,454
13,981
9,680
107,987
3,152
3,152
0
0
0
155,572
0
0
120,389
100,917
99,881
114,639
114,971
117,822
63,741
67,482
101
0
0
0
0
0
0
0
311,488
483,771
456,798
358,629
-251,839
1,471
151,471
151,561
150,000
151,471
151,471
151,471
34,171
35,215
14,166
60,882
53,448
9,037
9,687
9,632
18,069
43,757
545,121
562,657
540,725
583,401
75,477
76,157
40,891
110,710
126,657
59,235
63,930
138,697
169,330
134,956
69,807
69,807134,956169,330138,69763,93059,235126,657110,71040,89176,15775,477583,401540,725562,657545,12143,75718,0699,6329,6879,03753,44860,88214,16635,21534,171151,471151,471151,471150,000151,561151,4711,471-251,839358,629456,798483,771311,488000000010167,48263,741117,822114,971114,63999,881100,917120,38900155,5720003,1523,152107,9879,68013,98115,45415,4152,9983,0623,1162,6642,7292,8212,8632,7412,7702,7982,8272,8552,8844,0322,3600000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,674
8,570
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,667
33,667
19,654
9,406
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000009,40619,65433,66731,66700000000000000008,5708,674000000000000000000000000000000
> Total Liabilities 
2,673
0
0
0
61,890
78,419
17,798
17,564
19,965
19,238
21,474
20,177
36,569
35,771
37,037
39,750
38,832
37,313
40,388
312,156
294,623
283,444
380,877
375,624
352,551
355,785
334,171
313,647
303,420
291,576
274,702
251,963
235,032
223,485
204,277
182,350
163,920
142,917
130,190
145,192
153,467
160,022
154,383
149,921
150,183
125,324
90,390
81,879
143,328
132,280
122,167
114,540
121,796
127,898
283,680
297,942
342,589
303,025
311,317
299,446
228,299
168,334
168,587
197,535
272,837
467,013
959,216
934,535
956,442
929,895
1,974,641
2,092,260
2,390,814
2,329,079
2,656,067
2,716,420
3,055,101
3,032,379
3,154,377
3,602,893
3,704,582
3,651,180
3,810,527
4,004,939
4,050,524
4,050,5244,004,9393,810,5273,651,1803,704,5823,602,8933,154,3773,032,3793,055,1012,716,4202,656,0672,329,0792,390,8142,092,2601,974,641929,895956,442934,535959,216467,013272,837197,535168,587168,334228,299299,446311,317303,025342,589297,942283,680127,898121,796114,540122,167132,280143,32881,87990,390125,324150,183149,921154,383160,022153,467145,192130,190142,917163,920182,350204,277223,485235,032251,963274,702291,576303,420313,647334,171355,785352,551375,624380,877283,444294,623312,15640,38837,31338,83239,75037,03735,77136,56920,17721,47419,23819,96517,56417,79878,41961,8900002,673
   > Total Current Liabilities 
2,673
0
0
0
3,844
8,193
8,704
6,640
6,575
6,138
9,021
8,002
18,484
19,990
20,601
21,530
22,925
23,498
27,106
87,456
82,091
84,910
105,727
102,024
99,452
104,251
102,331
101,121
110,733
98,571
271,153
99,433
102,046
219,060
19,329
17,716
80,990
66,638
19,747
20,007
153,467
160,022
53,066
54,895
150,183
125,324
90,390
81,879
143,328
132,280
122,167
57,112
121,796
127,898
70,575
81,761
192,589
95,786
108,726
101,045
198,299
138,334
113,659
121,503
242,837
137,736
929,216
352,864
956,442
338,791
384,302
480,241
1,127,995
494,825
554,648
610,656
1,191,301
605,963
657,685
772,791
767,915
673,391
769,377
949,785
967,786
967,786949,785769,377673,391767,915772,791657,685605,9631,191,301610,656554,648494,8251,127,995480,241384,302338,791956,442352,864929,216137,736242,837121,503113,659138,334198,299101,045108,72695,786192,58981,76170,575127,898121,79657,112122,167132,280143,32881,87990,390125,324150,18354,89553,066160,022153,46720,00719,74766,63880,99017,71619,329219,060102,04699,433271,15398,571110,733101,121102,331104,25199,452102,024105,72784,91082,09187,45627,10623,49822,92521,53020,60119,99018,4848,0029,0216,1386,5756,6408,7048,1933,8440002,673
       Short-term Debt 
0
0
0
0
558
0
0
379
790
1,288
1,776
1,765
1,876
2,006
2,721
3,046
3,217
3,295
3,617
3,705
3,795
3,888
3,968
3,227
6,111
1,033
1,829
1,057
5,644
-8,656
-7,991
237
0
-12,534
-81,205
-76,211
0
0
-23,089
-19,837
4,248
7,315
5,232
2,023
2,925
28,113
8,178
5,858
5,011
7,025
5,313
0
6,732
7,577
0
0
11,498
150,000
150,000
150,000
10,973
15,275
30,000
0
62,885
16,977
306,558
28,165
303,823
29,043
33,447
32,192
329,911
38,917
39,362
40,612
321,895
41,290
41,236
41,581
41,967
43,055
42,074
41,516
96,501
96,50141,51642,07443,05541,96741,58141,23641,290321,89540,61239,36238,917329,91132,19233,44729,043303,82328,165306,55816,97762,885030,00015,27510,973150,000150,000150,00011,498007,5776,73205,3137,0255,0115,8588,17828,1132,9252,0235,2327,3154,248-19,837-23,08900-76,211-81,205-12,5340237-7,991-8,6565,6441,0571,8291,0336,1113,2273,9683,8883,7953,7053,6173,2953,2173,0462,7212,0061,8761,7651,7761,288790379005580000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
150,000
150,000
150,000
150,000
30,000
30,000
30,000
0
0
16,977
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000016,9770030,00030,00030,000150,000150,000150,000150,00000000000000000000000000000000000000000000000000000000000
       Accounts payable 
674
0
0
0
1,510
3,636
1,810
1,450
910
1,653
1,612
1,985
1,975
3,928
3,698
2,456
4,085
3,007
5,669
7,057
3,826
9,084
6,240
3,342
2,588
8,729
6,463
8,426
12,489
15,742
17,823
6,561
9,312
17,850
7,949
5,486
5,800
4,339
5,519
5,093
4,420
3,105
4,534
2,728
5,896
5,037
6,168
5,201
15,111
15,486
15,715
14,272
16,787
17,442
12,824
23,137
54,465
25,371
23,170
9,239
28,355
13,206
11,988
21,772
59,708
22,671
71,215
39,392
49,884
40,484
26,125
27,872
51,966
45,381
53,079
40,048
73,426
54,916
52,418
40,572
98,094
62,237
59,746
73,840
55,519
55,51973,84059,74662,23798,09440,57252,41854,91673,42640,04853,07945,38151,96627,87226,12540,48449,88439,39271,21522,67159,70821,77211,98813,20628,3559,23923,17025,37154,46523,13712,82417,44216,78714,27215,71515,48615,1115,2016,1685,0375,8962,7284,5343,1054,4205,0935,5194,3395,8005,4867,94917,8509,3126,56117,82315,74212,4898,4266,4638,7292,5883,3426,2409,0843,8267,0575,6693,0074,0852,4563,6983,9281,9751,9851,6121,6539101,4501,8103,6361,510000674
       Other Current Liabilities 
1,999
0
0
0
1,443
4,141
5,443
3,740
3,875
1,678
4,243
2,986
3,899
3,669
4,583
5,104
4,479
7,297
9,980
15,042
15,221
13,116
14,713
15,407
10,889
10,389
9,908
8,381
10,671
9,592
8,263
11,365
11,116
12,534
11,864
12,714
12,824
13,889
1,364
2,755
12,508
10,074
9,740
16,586
15,272
25,379
16,494
20,522
56,352
49,104
38,423
28,867
29,960
31,983
38,866
37,537
43,694
33,660
45,762
53,274
74,191
66,322
92,510
96,287
116,290
94,968
148,314
177,948
206,531
183,221
217,143
305,576
393,817
294,187
364,063
414,952
494,137
377,919
449,739
546,430
585,749
532,305
632,180
757,289
713,013
713,013757,289632,180532,305585,749546,430449,739377,919494,137414,952364,063294,187393,817305,576217,143183,221206,531177,948148,31494,968116,29096,28792,51066,32274,19153,27445,76233,66043,69437,53738,86631,98329,96028,86738,42349,10456,35220,52216,49425,37915,27216,5869,74010,07412,5082,7551,36413,88912,82412,71411,86412,53411,11611,3658,2639,59210,6718,3819,90810,38910,88915,40714,71313,11615,22115,0429,9807,2974,4795,1044,5833,6693,8992,9864,2431,6783,8753,7405,4434,1411,4430001,999
   > Long-term Liabilities 
0
0
0
0
58,046
70,226
9,094
10,924
13,390
13,100
12,453
12,175
18,085
15,781
16,436
18,220
15,907
13,815
13,282
224,700
212,532
198,534
275,150
273,600
253,099
251,534
231,840
212,526
192,687
193,005
3,549
152,530
132,986
4,425
184,948
164,634
82,930
76,279
110,443
125,185
105,122
110,272
101,317
95,026
96,319
41,493
36,645
25,030
47,994
51,587
55,569
57,428
59,697
61,529
213,105
216,181
150,000
207,239
202,591
198,401
30,000
30,000
54,928
76,032
30,000
329,277
30,000
581,671
603,848
591,104
1,590,339
1,612,019
1,262,819
1,834,254
2,101,419
2,105,764
1,863,800
2,426,416
2,496,692
2,830,102
2,936,667
2,977,789
3,041,150
3,055,154
3,082,738
3,082,7383,055,1543,041,1502,977,7892,936,6672,830,1022,496,6922,426,4161,863,8002,105,7642,101,4191,834,2541,262,8191,612,0191,590,339591,104603,848581,67130,000329,27730,00076,03254,92830,00030,000198,401202,591207,239150,000216,181213,10561,52959,69757,42855,56951,58747,99425,03036,64541,49396,31995,026101,317110,272105,122125,185110,44376,27982,930164,634184,9484,425132,986152,5303,549193,005192,687212,526231,840251,534253,099273,600275,150198,534212,532224,70013,28213,81515,90718,22016,43615,78118,08512,17512,45313,10013,39010,9249,09470,22658,0460000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
150,000
150,000
150,000
150,000
150,000
150,000
30,000
30,000
30,000
30,000
30,000
30,000
30,000
0
0
0
0
0
191,278
0
0
0
675,697
0
0
1,015,975
1,016,942
1,017,887
1,018,843
0
0
001,018,8431,017,8871,016,9421,015,97500675,697000191,2780000030,00030,00030,00030,00030,00030,00030,000150,000150,000150,000150,000150,000150,000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,674
8,570
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,667
33,667
19,654
9,406
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000009,40619,65433,66731,66700000000000000008,5708,674000000000000000000000000000000
       Other Liabilities 
0
0
0
0
1,556
1,472
3,389
4,333
6,979
6,622
6,266
6,393
12,566
10,461
10,102
11,783
9,988
8,750
8,376
220,754
209,569
196,579
274,212
272,881
252,853
251,534
231,840
212,526
192,493
193,005
172,669
152,530
132,986
124,141
103,743
88,423
82,930
76,279
73,126
90,434
105,122
110,272
101,317
95,026
96,319
41,493
36,645
25,030
47,994
51,587
55,569
57,428
59,697
61,529
63,105
66,181
60,890
57,239
52,591
48,401
54,048
22,951
24,928
46,032
63,343
5,550
323,401
305,215
327,713
315,322
1,308,721
1,314,757
1,423,842
1,354,649
1,379,709
1,385,935
1,402,347
1,472,318
1,546,953
1,547,804
406,371
415,303
451,183
476,820
0
0476,820451,183415,303406,3711,547,8041,546,9531,472,3181,402,3471,385,9351,379,7091,354,6491,423,8421,314,7571,308,721315,322327,713305,215323,4015,55063,34346,03224,92822,95154,04848,40152,59157,23960,89066,18163,10561,52959,69757,42855,56951,58747,99425,03036,64541,49396,31995,026101,317110,272105,12290,43473,12676,27982,93088,423103,743124,141132,986152,530172,669193,005192,493212,526231,840251,534252,853272,881274,212196,579209,569220,7548,3768,7509,98811,78310,10210,46112,5666,3936,2666,6226,9794,3333,3891,4721,5560000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
172,501
152,530
132,843
123,074
103,001
87,694
82,214
75,576
72,436
89,913
100,874
110,272
101,317
95,026
96,319
40,493
35,645
24,530
47,994
51,587
55,569
57,428
58,396
60,156
61,328
64,190
57,823
54,055
49,776
45,559
49,701
18,493
16,220
40,074
57,920
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000057,92040,07416,22018,49349,70145,55949,77654,05557,82364,19061,32860,15658,39657,42855,56951,58747,99424,53035,64540,49396,31995,026101,317110,272100,87489,91372,43675,57682,21487,694103,001123,074132,843152,530172,501000000000000000000000000000000
> Total Stockholder Equity
13,438
0
0
0
-26,707
-39,080
50,675
44,981
46,142
39,829
29,388
23,071
61,779
117,916
110,077
104,777
201,174
190,027
179,270
192,935
199,168
202,812
199,169
204,557
202,125
198,744
184,482
182,021
177,965
171,830
165,478
160,643
158,233
145,567
136,551
127,873
117,997
197,378
188,287
177,160
134,053
311,556
308,175
297,582
270,347
954,973
942,269
904,478
936,267
1,496,510
1,408,604
1,321,604
1,264,714
1,189,051
1,098,482
1,014,968
920,221
830,901
1,122,966
1,058,835
1,766,431
1,754,805
1,620,802
1,478,119
1,301,965
1,546,986
1,757,195
1,607,087
1,438,692
1,349,729
1,399,726
1,215,023
1,016,247
926,190
853,362
755,893
588,203
401,166
176,040
-67,638
-158,223
-259,240
-408,131
-165,866
-220,644
-220,644-165,866-408,131-259,240-158,223-67,638176,040401,166588,203755,893853,362926,1901,016,2471,215,0231,399,7261,349,7291,438,6921,607,0871,757,1951,546,9861,301,9651,478,1191,620,8021,754,8051,766,4311,058,8351,122,966830,901920,2211,014,9681,098,4821,189,0511,264,7141,321,6041,408,6041,496,510936,267904,478942,269954,973270,347297,582308,175311,556134,053177,160188,287197,378117,997127,873136,551145,567158,233160,643165,478171,830177,965182,021184,482198,744202,125204,557199,169202,812199,168192,935179,270190,027201,174104,777110,077117,91661,77923,07129,38839,82946,14244,98150,675-39,080-26,70700013,438
   Common Stock
0
0
0
0
0
0
200
201
208
209
209
212
267
320
321
322
371
375
376
406
408
408
411
414
414
414
417
418
418
419
421
422
423
424
427
427
427
519
520
524
525
621
624
632
637
755
763
767
772
842
845
847
851
855
856
858
859
861
917
924
997
1,005
1,005
1,009
1,011
1,064
1,110
1,113
1,122
1,131
1,156
1,161
1,164
1,173
1,186
1,195
1,202
1,207
1,210
1,230
1,240
1,243
1,250
1,255
1,259
1,2591,2551,2501,2431,2401,2301,2101,2071,2021,1951,1861,1731,1641,1611,1561,1311,1221,1131,1101,0641,0111,0091,0051,005997924917861859858856855851847845842772767763755637632624621525524520519427427427424423422421419418418417414414414411408408406376375371322321320267212209209208201200000000
   Retained Earnings Total Equity00-7,019,474-6,743,450-6,569,349-6,361,856-5,955,936-5,678,534-5,438,193-5,179,733-4,975,219-4,785,660-4,585,369-4,341,829-4,088,538-3,909,309-3,727,088-3,450,903-3,242,368-3,022,887-2,840,972-2,629,531-2,384,249-2,220,689-2,147,685-2,005,458-1,882,521-1,764,101-1,656,811-1,543,877-1,439,806-1,349,677-1,246,703-1,155,982-1,079,190-1,007,407-956,630-935,241-891,252-847,178-596,235-563,878-534,192-516,023-507,010-444,822-425,320-412,364-400,996-386,693-373,456-359,632-343,347-336,417-326,787000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-4,605
-7,672
-6,162
-4,318
-3,277
-2,934
-2,973
-2,889
-2,602
-1,682
-819
128
551
571
536
145
300
646
-1,660
-1,099
1,186
623
1,621
1,889
716
823
1,286
1,288
714
-18
-246
-151
-165
-37
-62
108
15,662
20,821
28,130
27,168
19,717
25,030
21,983
15,186
48,763
52,385
18,762
-7,219
4,369
-9,011
-28,296
-27,778
-33,441
-33,828
-33,959
-33,741
-34,433
-34,853
-33,807
-33,392
-33,213
-32,853
-35,831
-34,371
-36,518
-32,059
-33,212
-37,193
-43,622
-36,717
-36,081
-34,230
-33,259
-38,065
-42,224
-43,783
-44,654
-39,124
-37,080
-32,339
-23,375
-23,375-32,339-37,080-39,124-44,654-43,783-42,224-38,065-33,259-34,230-36,081-36,717-43,622-37,193-33,212-32,059-36,518-34,371-35,831-32,853-33,213-33,392-33,807-34,853-34,433-33,741-33,959-33,828-33,441-27,778-28,296-9,0114,369-7,21918,76252,38548,76315,18621,98325,03019,71727,16828,13020,82115,662108-62-37-165-151-246-187141,2881,2868237161,8891,6216231,186-1,099-1,660646300145536571551128-819-1,682-2,602-2,889-2,973-2,934-3,277-4,318-6,162-7,672-4,6050000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
490,558
495,350
500,443
504,793
509,826
514,290
518,731
609,260
613,149
621,350
624,876
806,137
813,613
833,660
846,228
1,776,366
1,810,775
1,823,766
1,843,362
2,450,690
2,468,187
2,483,958
2,506,197
2,546,884
2,565,728
2,585,765
2,609,614
2,627,969
3,038,529
3,097,110
3,947,552
4,009,342
4,037,853
4,140,033
4,175,139
4,601,662
5,034,284
5,091,248
5,201,176
5,289,966
5,520,320
5,592,884
5,644,074
5,747,394
5,863,476
5,968,661
6,058,453
6,116,558
6,172,990
6,336,771
6,454,540
6,522,091
6,647,173
0
0
006,647,1736,522,0916,454,5406,336,7716,172,9906,116,5586,058,4535,968,6615,863,4765,747,3945,644,0745,592,8845,520,3205,289,9665,201,1765,091,2485,034,2844,601,6624,175,1394,140,0334,037,8534,009,3423,947,5523,097,1103,038,5292,627,9692,609,6142,585,7652,565,7282,546,8842,506,1972,483,9582,468,1872,450,6901,843,3621,823,7661,810,7751,776,366846,228833,660813,613806,137624,876621,350613,149609,260518,731514,290509,826504,793500,443495,350490,558000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
7,416
12,525
39,053
43,858
112,216
112,158
112,902
117,176
170,033
234,057
235,264
236,416
340,779
351,252
353,221
420,039
424,453
428,990
440,410
448,092
452,767
457,838
465,277
471,755
476,663
482,743
490,558
495,350
500,443
504,793
509,826
514,290
518,731
609,260
613,149
621,350
624,876
806,137
813,613
833,660
846,228
1,776,366
1,810,775
1,823,766
1,843,362
2,450,690
2,468,187
2,483,958
2,506,197
2,546,884
2,565,728
2,585,765
2,609,614
2,627,969
3,038,529
3,097,110
3,947,552
4,009,342
4,037,853
4,140,033
4,175,139
4,601,662
5,034,284
5,091,248
5,201,176
5,289,966
5,520,320
5,592,884
5,644,074
5,747,394
5,863,476
5,968,661
6,058,453
6,116,558
6,172,990
6,336,771
6,454,540
6,522,091
6,647,173
6,736,939
6,811,063
6,811,0636,736,9396,647,1736,522,0916,454,5406,336,7716,172,9906,116,5586,058,4535,968,6615,863,4765,747,3945,644,0745,592,8845,520,3205,289,9665,201,1765,091,2485,034,2844,601,6624,175,1394,140,0334,037,8534,009,3423,947,5523,097,1103,038,5292,627,9692,609,6142,585,7652,565,7282,546,8842,506,1972,483,9582,468,1872,450,6901,843,3621,823,7661,810,7751,776,366846,228833,660813,613806,137624,876621,350613,149609,260518,731514,290509,826504,793500,443495,350490,558482,743476,663471,755465,277457,838452,767448,092440,410428,990424,453420,039353,221351,252340,779236,416235,264234,057170,033117,176112,902112,158112,21643,85839,05312,5257,4160000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,828,292
Cost of Revenue-310,406
Gross Profit1,517,8861,517,886
 
Operating Income (+$)
Gross Profit1,517,886
Operating Expense-1,800,061
Operating Income-282,175-282,175
 
Operating Expense (+$)
Research Development1,004,415
Selling General Administrative795,646
Selling And Marketing Expenses0
Operating Expense1,800,0611,800,061
 
Net Interest Income (+$)
Interest Income95,561
Interest Expense-121,221
Other Finance Cost-0
Net Interest Income-25,660
 
Pretax Income (+$)
Operating Income-282,175
Net Interest Income-25,660
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-433,517-130,833
EBIT - interestExpense = -403,396
-433,517
-319,021
Interest Expense121,221
Earnings Before Interest and Taxes (EBIT)-282,175-312,296
Earnings Before Interest and Taxes (EBITDA)-228,121
 
After tax Income (+$)
Income Before Tax-433,517
Tax Provision-6,725
Net Income From Continuing Ops-440,242-440,242
Net Income-440,242
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,110,467
Total Other Income/Expenses Net-151,34225,660
 

Technical Analysis of Alnylam
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alnylam. The general trend of Alnylam is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alnylam's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alnylam Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 182.36 < 191.72 < 199.38.

The bearish price targets are: 143.52 > 135.46 > 122.57.

Tweet this
Alnylam Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alnylam Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alnylam Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alnylam Pharmaceuticals Inc. The current macd is -2.72611686.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Alnylam price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Alnylam. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Alnylam price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Alnylam Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAlnylam Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alnylam Pharmaceuticals Inc. The current adx is 25.80.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Alnylam shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Alnylam Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alnylam Pharmaceuticals Inc. The current sar is 143.66.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Alnylam Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alnylam Pharmaceuticals Inc. The current rsi is 52.16. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Alnylam Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAlnylam Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alnylam Pharmaceuticals Inc. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Alnylam price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Alnylam Pharmaceuticals Inc Daily Stochastic Oscillator ChartAlnylam Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alnylam Pharmaceuticals Inc. The current cci is 146.99.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Alnylam Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAlnylam Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alnylam Pharmaceuticals Inc. The current cmo is 26.25.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Alnylam Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAlnylam Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alnylam Pharmaceuticals Inc. The current willr is -7.65920826.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Alnylam Pharmaceuticals Inc Daily Williams %R ChartAlnylam Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alnylam Pharmaceuticals Inc. The current atr is 4.60201622.

Alnylam Pharmaceuticals Inc Daily Average True Range (ATR) ChartAlnylam Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alnylam Pharmaceuticals Inc. The current obv is -7,437,667.

Alnylam Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAlnylam Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alnylam Pharmaceuticals Inc. The current mfi is 59.46.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Alnylam Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAlnylam Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alnylam Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-26BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.

6.3. Candlestick Patterns

Alnylam Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alnylam Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.162
Ma 20Greater thanMa 50149.493
Ma 50Greater thanMa 100161.829
Ma 100Greater thanMa 200169.685
OpenGreater thanClose152.830
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Alnylam with someone you think should read this too:
  • Are you bullish or bearish on Alnylam? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alnylam? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alnylam Pharmaceuticals Inc

I send you an email if I find something interesting about Alnylam Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Alnylam Pharmaceuticals Inc.

Receive notifications about Alnylam Pharmaceuticals Inc in your mailbox!